Tiotropium

Cystic Fibrosis

Boehringer IngelheimSmall moleculePhase 3Dormant

BB

66/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 62/ 100
Competitive Position: 73/ 100

Competitive context

82 Active assets in the Cystic Fibrosis cohort.

Asset / Sponsor	Phase	Rating
Tezacaftor Vertex Pharmaceuticals Incorporated	Phase 4	A
Liprotamase Anthera Pharmaceuticals	Phase 4	BBB
Lumacaftor Hospices Civils de Lyon	Phase 4	BBB
Ivacaftor Meyer Children's Hospital IRCCS	Phase 4	BBB
ELEXACAFTOR Meyer Children's Hospital IRCCS	Phase 4	BBB

View all 50 →

Same molecule, other indications

Tiotropium is also rated in:

chronic obstructive pulmonary diseaseDormant

B

Indicative ·

60 / 100

non-small cell lung carcinomaDormant

CCC

Indicative ·

48 / 100

asthmaDormant

D

Indicative ·

30 / 100

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.